Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.
Ann Thorac Surg. 2022 Jan;113(1):244-249. doi: 10.1016/j.athoracsur.2021.01.053. Epub 2021 Feb 16.
While robotic-assisted lung resection has seen a significant rise in adoption, concerns remain regarding initial programmatic outcomes and potential increased costs. We present our initial outcomes and cost analysis since initiation of a robotic lung resection program.
Patients undergoing either video-assisted thoracoscopic lobectomy or segmentectomy (VATS) or robotic-assisted lobectomy or segmentectomy (RALS) between August of 2014 and January of 2017 underwent retrospective review. Patients underwent 1:1 propensity matching based on preoperative characteristics. Perioperative and 30-day outcomes were compared between groups. Detailed activity-based costing analysis was performed on individual patient encounters taking into effect direct and indirect controllable costs, including robotic operative supplies.
There were no differences in 30-day mortality between RALS (n = 74) and VATS (n = 74) groups (0% vs 1.4%; P = 1). RALS patients had a decreased median length of stay (4 days vs 7 days; P < .001) and decreased median chest tube duration (3 days vs 5 days, P < .001). Total direct costs, including direct supply costs, were not significantly different between RALS and VATS ($6621 vs $6483; P = .784). Median total operating costs and total unit support costs, which are closely correlated to length of stay, were lower in the RALS group. Overall median controllable costs were significantly different between RALS and VATS ($16,352 vs $21,154; P = .025).
A potentially cost-advantageous robotic-assisted pulmonary resection program can be initiated within the context of an existing minimally invasive thoracic surgery program while maintaining good clinical outcomes when compared with traditional VATS. Process-of-care changes associated with RALS may account for decreased costs in this setting.
虽然机器人辅助肺切除术的应用显著增加,但人们仍对初始项目结果和潜在的成本增加存在担忧。我们报告了机器人肺切除术项目启动以来的初步结果和成本分析。
对 2014 年 8 月至 2017 年 1 月期间行电视辅助胸腔镜肺叶切除术或肺段切除术(VATS)或机器人辅助肺叶切除术或肺段切除术(RALS)的患者进行回顾性分析。根据术前特征进行 1:1 倾向匹配。比较两组围手术期和 30 天结果。对每位患者的就诊情况进行详细的基于活动的成本分析,考虑直接和间接可控成本,包括机器人手术耗材。
RALS(n=74)和 VATS(n=74)组的 30 天死亡率无差异(0% vs 1.4%;P=1)。RALS 患者的中位住院时间(4 天 vs 7 天;P<0.001)和中位胸腔引流管时间(3 天 vs 5 天;P<0.001)均缩短。RALS 和 VATS 之间的总直接成本(包括直接供应成本)无显著差异(RALS 组为 6621 美元,VATS 组为 6483 美元;P=0.784)。RALS 组的中位总手术成本和总单位支持成本(与住院时间密切相关)较低。RALS 和 VATS 之间的总体中位可控成本差异显著(RALS 组为 16352 美元,VATS 组为 21154 美元;P=0.025)。
在现有的微创胸外科项目背景下,启动一个具有潜在成本优势的机器人辅助肺切除项目,同时保持与传统 VATS 相比良好的临床结果是可行的。RALS 相关的治疗流程改变可能导致该环境下成本降低。